What does Aquestive do and what are its main business segments?

What guidance did Aquestive's management provide for the next earnings period?

What factors drove the changes in Aquestive's revenue and profit?

What is the market's earnings forecast for Aquestive next quarter?

What is Aquestive's gross profit margin?

Did Aquestive beat or miss consensus estimates last quarter?

What were the key takeaways from Aquestive's earnings call?

What is the revenue and EPS growth rate for Aquestive year over year?

- **FDA Path Clarified**: Type A meeting expected within 30 days; resubmission guidance maintained for Q3 2026. FDA denied competitor petition, reinforcing Anaphylm's clinical strength.
- **Expanded Commercial Ambition**: 75-rep launch team (50% increase) signals confidence in U.S. market potential. Secured $75M RTW financing extension with $5M equity investment.
- **Clinical Momentum**: AQST-108 Phase I data highlights new indication opportunities. Anaphylm PK study includes IM epinephrine comparison to address FDA questions.
- **Market Growth**: U.S. allergy market up 9% Q4 2025, with 90% prescriptions on auto-injectors. Anaphylm's oral delivery positioned to capture share as first non-device option.

**【CEO Summary Section】**
- **FDA Progress and Clinical Team Strengthening**: Submitted Type A meeting request with FDA for Anaphylm NDA resubmission, expecting discussion within 30 days. Added Dr. Matt Greenhawt (AAAAI Distinguished Clinician Award) and Dr. Matthew Davis to enhance clinical expertise. Expanded medical affairs team to double size for broader physician engagement.
- **Commercial Launch Preparation**: Guided to launch with 75 sales reps (50% increase from prior guidance) upon FDA approval, aiming for cash-neutral position by end-2027. Secured $75M revenue interest financing extension with RTW until June 2027, plus $5M strategic investment.
- **Market Dynamics**: U.S. allergy market grew 9% Q4 2025, with 90% prescriptions on auto-injectors. Anaphylm's oral delivery and ease of use positioned to disrupt market; 75% of patients prefer film over auto-injectors in trials.
- **Pipeline and Licensing**: Progressing AQST-108 Phase I trial for potential new indications. Focused on out-licensing Libervant in U.S. and Anaphylm ex-U.S., with active discussions for both.

**【CFO Financial Commentary】**
- **2025 Financials**: Total revenue $44.5M (down 3% YoY), driven by Suboxone and Ondif. Net loss $83.8M (up 90% YoY) due to higher SG&A (legal expenses $14.3M, commercial prep $9.6M). Ended 2025 with $121M cash.
- **2026 Guidance**: Revenue $46-50M, non-GAAP EBITDA loss $30-35M. Cash runway to $70M (excluding RTW or licensing proceeds). Costs include NDA resubmission, PK/human factors studies, and AQST-108 Phase I.

**【Q&A Highlights】**
- **FDA Interaction**: FDA denied competitor's citizens petition, validating Anaphylm's clinical package. PK study design aligned with FDA requests, with flexibility to adjust based on Type A meeting feedback.
- **Sales Force Expansion**: 75 reps target deeper allergist and pediatrician penetration, with territories optimized for efficiency. DTC strategy deferred until market share builds, leveraging competitor DTC spend to grow overall market.
- **Clinical Trials**: AQST-108 Phase I data shows potential for alopecia areata and other topical indications. Anaphylm PK study will include IM epinephrine comparison and new IFU validation.
- **Timing Assumptions**: Europe/Canada filings post-U.S. approval. 8-week window from FDA approval to commercial launch (product distribution + rep deployment).

Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript

- **FDA-Ready for Q1 2026 Launch**: Anaphylm pre-launch activities fully executed; 75%+ allergist awareness and 35/35 HCPs prefer Anaphylm over nasal spray in trials.
- **Strong Financial Position**: $129M cash post-$85M equity raise; debt refinancing targeting low-cost, long-term partner.
- **Pipeline Expansion**: AQST-108 Phase IIa trial planned for 40-60 patients; exploring non-topical Adrenaverse delivery methods.
- **Market Growth**: Epinephrine scripts up 8.8% Q3, 95% auto-injector share; Anaphylm targets 200+ scripts/allergist.

**【CEO Summary Section】**
- Anaphylm (sublingual epinephrine film) on track for Q1 2026 launch if FDA approves by January 31, 2026. Pre-launch activities fully underway, including hiring district managers and finalizing supply chain. 
- Anaphylm awareness among allergists exceeds 75%, with 25% completing CME training. 35/35 surveyed HCPs preferred Anaphylm over nasal spray in mock comparison.
- Expanded leadership team: Dr. Gary Slatko as Interim CMO, Dr. Matthew Davis as Chief Development Officer for Adrenaverse platform. 
- AQST-108 (alopecia areata) IND submission planned for Q1 2026, with Phase IIa trial targeting 40-60 participants.
- International expansion: Canada filing expected Q1 2026, EMA feedback due Q1 2026.

**【CFO Financial Commentary】**
- Q3 2025 revenue $12.8M (flat YoY due one-time deferred revenue recognition in 2024). Non-GAAP adj. EBITDA loss $8.6M vs. $6.6M prior year.
- Completed $85M equity raise and $75M commercial launch financing. Total cash $129.1M as of Q3, sufficient for 2026 launch.
- R&D expenses down 15% YoY to $14M (lower clinical trial costs). SG&A up 37% YoY to $47M (pre-launch spending).
- Debt refinancing underway; targeting new partner with long maturity and low coupon.

**【Q&A Highlights】**
- Competitor citizens petition deemed factually flawed; no FDA timeline impact. Anaphylm pricing strategy: patient-first, responsible WAC with co-pay savings programs.
- International partnerships likely post-FDA approval; focus on Canada, EU, Japan. 
- Adrenaverse pipeline: exploring non-topical delivery methods (capsules, injectables) beyond AQST-108.
- Manufacturing capacity >10x current epinephrine market (150M doses/year).

Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript

- **FDA Milestone**: Anaphylm on track for January 2026 FDA decision; 930+ exposure clinical package strengthens approval odds.
- **Market Potential**: $2B+ global market target with 10M+ annual prescriptions; 90% shift to non-injectables expected.
- **Financial Health**: $60M cash; 2025 adj. EBITDA loss guidance of $47-51M reflects pre-launch investment.
- **Patient Access**: Day-1 cash pay program to bypass payer barriers; 80%+ coverage target within 6 months.
- **Pipeline Growth**: AQST-108 topical gel IND submission planned; international product revenue up 19% YoY.

**【CEO Summary Section】**
- **Anaphylm FDA Update**: On track for January 2026 PDUFA action date; 120-day safety update submitted with no new concerns. Mid-cycle review nearing completion, potential advisory committee decision pending.
- **Pre-Commercial Launch**: $60M cash on hand; exploring financing options (EU rights, debt, revenue-sharing). Global market potential of $2B+ with 10M+ annual prescriptions.
- **Patient Access Strategy**: Launching day-1 cash pay program to bypass payer barriers; 90% of market expected to shift from injectables to non-injectables over time.
- **Pipeline Progress**: AQST-108 topical gel IND submission planned for late 2025; international product growth offsets Suboxone decline.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Total revenue $10M (3% YoY growth, excluding one-time 2024 deferred revenue). Manufacturing revenue up 19% to $9.6M; R&D expenses stable at $9.5M.
- **Financial Position**: Net loss $13.5M; cash balance $60.5M. 2025 guidance: $44-50M revenue, $47-51M adj. EBITDA loss.
- **Cost Management**: $4.3M FDA PDUFA fee; $4.2M pre-launch commercial spending.

**【Q&A Key Highlights】**
- **FDA Advisory Committee**: 50% likelihood; robust clinical package with 930+ exposures across 10 studies. Mid-cycle review expected to clarify need for AdComm.
- **Payer Strategy**: Patient-first approach with co-pay buy-downs; 80%+ coverage target within 6 months. Competitor's CRL highlighted need to address FDA requests upfront.
- **International Expansion**: EU and Canada regulatory meetings scheduled; pediatric data supports 30kg+ indication.
- **Competitive Landscape**: Nasal spray competitor facing access barriers; Anaphylm's oral film convenience优势 expected to drive carry rate improvement.


Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

- **FDA Progress**: Anaphylm on track for early 2026 FDA decision; prelaunch activities include 25+ conferences and 16+ publications.
- **Commercial Strategy**: 50-person salesforce targeting top allergists; 80% payer coverage within 6 months of launch.
- **Financial Outlook**: Q1 2025 revenue $8.7M (28% YoY decline); revised 2025 guidance: $44M-$50M revenue, $47M-$51M EBITDA loss.
- **Funding**: Exploring ex-U.S. partnerships and debt refinancing to support 2026+ launch.

**【CEO Summary Section】**
- **FDA Review Progress**: Anaphylm under FDA review with an anticipated action date in early 2026. The company is in the commercial prelaunch phase, focusing on team recruitment, healthcare provider awareness, and payer engagement.
- **Commercial Readiness**: 
  - **Team**: Hired a team with experience launching billion-dollar brands (e.g., EpiPen) and market access experts.
  - **Awareness**: Attending 25+ conferences and publishing 16+ posters/manuscripts by year-end; plans to publish nearly 30 by FDA action date.
  - **Payer Contracts**: Leveraging existing contracts from Libervant to accelerate Anaphylm launch.
  - **Product Messaging**: Emphasizes portability (fits on phone) and convenience, with 95% of surveyed HCPs believing patients will prefer Anaphylm.
- **Market Expansion**: Targeting 4,000+ top allergists and pediatricians with a 50-person salesforce initially, aiming for 80% payer coverage within 6 months of launch.
- **Strategic Moves**: Pausing AQST-108 studies to allocate capital to Anaphylm launch; exploring ex-U.S. partnerships and debt refinancing for long-term funding.

**【CFO Financial Commentary】**
- **Q1 2025 Results**: 
  - Total revenue: $8.7M (28% YoY decline) due to Suboxone decline, offset by Ondif growth.
  - Net loss: $22.9M ($0.24 EPS) vs. $12.8M ($0.17 EPS) in Q1 2024, driven by higher R&D and SG&A expenses.
  - Cash: $68.7M as of March 31, 2025.
- **Revised Guidance**: 
  - Total revenue: $44M-$50M (excluding Libervant for ages 2-5).
  - Non-GAAP EBITDA loss: $47M-$51M, reflecting pre-commercial Anaphylm spending.

**【Q&A Highlights】**
- **Salesforce & Manufacturing**: 50 sales reps targeting top prescribers; in-house manufacturing ensures readiness for day-one launch.
- **Payer Access**: Aiming for 80% coverage by 6 months post-approval, leveraging Libervant contracts.
- **DTC Strategy**: Parallel HCP and patient engagement; DTC campaign to launch after initial HCP awareness.
- **Ex-U.S. Partnerships**: Engaging with Canada, UK, and EMA; seeking non-dilutive funding via partnerships or refinancing.
- **Cash Requirements**: Sufficient runway through 2026; exploring ex-U.S. licensing and debt refinancing for long-term support.

Aquestive Therapeutics (AQST)-13 May 25-2025 Q1 Earnings call transcript

- **Anaphylm Regulatory Momentum**: Initiated NDA filing, pediatric data aligns with EpiPen label, potential H2 2025 Ad Comm.
- **Clinical Evidence Strength**: ATU study shows 65% physician preference vs. nasal spray despite competition.
- **Financial Positioning**: $71.5M cash as of Q4, raised $21.4M via ATM in Feb 2025.
- **Growth Drivers**: Anaphylm launch (Q1 2026), AQST-108 Phase 2a data, international expansion.
- **Risk Management**: Litigation over Libervant, $46-53M EBITDA loss guidance for 2025.


**【CEO Summary Section】**
- Initiated FDA NDA filing for Anaphylm, targeting June 2025 acceptance and Q1 2026 launch. 
- Completed pediatric study with data aligning to EpiPen 0.3mg label, to be included in NDA.
- Hired regulatory communications firm for potential H2 2025 Advisory Committee Meeting.
- Launched ATU study showing 65% physicians prefer Anaphylm over nasal spray despite current competition.
- Opened IND for AQST-108 topical epinephrine for alopecia areata, targeting Phase 2a start in Q2 2025.
- International expansion plans for Anaphylm in EU, UK, Canada.
- 2025 milestones: NDA acceptance, IND opening, clinical data sharing, commercial prep.

**【CFO Financial Commentary】**
- Q4 2024 Revenue: $11.9M (-10% YoY) due to Suboxone decline and lost Azstarys milestone.
- Full Year 2024 Revenue: $57.6M (+14% YoY) driven by one-time deferred revenue recognition.
- R&D Expenses: $20.3M (+55% YoY) for Anaphylm and AQST-108 trials.
- SG&A Expenses: $50.2M (+61% YoY) for Anaphylm commercial prep and Libervant litigation.
- Net Loss: $44.1M (-465% YoY) due to higher expenses and lower revenue.
- 2025 Guidance: $47-56M Revenue, $46-53M Non-GAAP EBITDA Loss.

**【Q&A Key Takeaways】**
- **Ad Comm Preparation**: Built mock committee, hired external experts, prepared for PK/PD, safety profile defense.
- **Market Potential**: 92% physicians aware of nasal spray but 65% prefer Anaphylm in ATU study.
- **Libervant Strategy**: Fighting court ruling while preparing for 2027 ODE expiration.
- **Sales Force Planning**: Target 100 reps post-approval, focusing on allergists and high-prescribing pediatricians.
- **Partnership Approach**: Open to US or global partner with scale and therapeutic commitment.
- **AQST-108 Opportunity**: $1B JAK inhibitor market with safety risks, topical epinephrine as alternative.


Aquestive Therapeutics (AQST)-6 Mar 25-2024 Q4 Earnings call transcript

Aquestive Therapeutics (AQST)-5 Nov 24-2024 Q3 Earnings call transcript

Aquestive Therapeutics (AQST)-7 Aug 24-2024 Q2 Earnings call transcript

Aquestive Therapeutics (AQST)-8 May 24-2024 Q1 Earnings call transcript

- **Anaphylm Milestone**: Pivotal study topline data expected in 2 weeks; global peak sales potential of $1 billion.
- **Libervant FDA Decision**: Action date April 28; U.S. launch discussions with epilepsy-focused partners.
- **Financial Strength**: 2023 revenue up 26% YoY; 2024 guidance includes $48–$51 million revenue and $22–$26 million EBITDA loss.
- **Pipeline Expansion**: AQST-108 in early clinical trials; Adrenaverse targeting multi-hundred-million-dollar opportunities.

**【CEO Summary Section】**
- **2023 Milestones**: Achieved solid revenue growth, improved non-GAAP adjusted EBITDA, and advanced Anaphylm (epinephrine sublingual film) and Libervant (diazepam buccal film) toward commercialization.
- **Strategic Focus**: 
  - **Anaphylm**: Pivotal study dosing completed; topline data expected in 2 weeks. Global peak sales potential of $1 billion. Commercial launch planned for H2 2025.
  - **Libervant**: FDA action date on April 28; U.S. launch discussions with epilepsy-focused partners. Ex-U.S. licensing opportunities being explored.
  - **Pipeline Refresh**: AQST-108 (topical cream) in early-stage clinical trials; Adrenaverse technology targeting multi-hundred-million-dollar opportunities.
- **Base Business Growth**: 2023 revenue up 26% YoY; partnerships in multiple geographies continue to expand.

**【CFO Financial Commentary】**
- **2023 Financials**: 
  - Total revenue: $50.6 million (6% YoY increase).
  - Non-GAAP adjusted EBITDA loss: $11.6 million (improved from $35.3 million YoY).
  - Cash balance: $23.9 million; ATM facility with $24 million available.
- **Refinancing**: $45 million senior secured notes at 13.5% interest, maturing 2028. Royalty agreements for Anaphylm and Libervant sales.
- **2024 Guidance**: 
  - Total revenue: $48–$51 million.
  - Non-GAAP adjusted EBITDA loss: $22–$26 million.
  - Excludes Libervant revenue.

**【Q&A Key Highlights】**
- **Anaphylm Data Expectations**: PK/PD sustainability and safety metrics to demonstrate superiority over auto-injectors. FDA Type C meeting feedback included.
- **Commercial Strategy**: 
  - **U.S. Launch**: H2 2025; focus on habit stacking (e.g., carrying film on phone case). Physician and patient advocacy outreach underway.
  - **Ex-U.S. Partnerships**: Actively negotiating licenses for Anaphylm and Libervant.
- **Libervant Update**: FDA action date April 28; self-launch contingency if no partner found.
- **Pipeline Progress**: AQST-108 in Phase 1; Adrenaverse targeting dermatology and other indications.
- **Financial Health**: 2024 cash runway extended via refinancing; no immediate need for additional capital.

Actual								-0.49	-0.07	-0.49	-0.6	-0.41	-0.33	-0.37	-0.72	-0.32	-0.36	-0.23	-0.23	0.11	-0.1	-0.03	-0.12	-0.17	-0.03	-0.13	-0.19	-0.24	-0.14	-0.14	-0.26
Forecast								-0.4667	-0.4433	-0.4567	-0.504	-0.425	-0.4367	-0.438	-0.466	-0.422	-0.358	-0.2886	-0.2257	-0.14	-0.1167	-0.1133	-0.085	-0.0888	-0.115	-0.1175	-0.1329	-0.165	-0.1667	-0.128	-0.13
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4.99%	+84.21%	-7.29%	-19.05%	+3.53%	+24.43%	+15.53%	-54.51%	+24.17%	-0.56%	+20.30%	-1.91%	+178.57%	+14.31%	+73.52%	-41.18%	-91.44%	+73.91%	-10.64%	-42.96%	-45.45%	+16.02%	-9.38%	-100.00%

AQST

AQST fundamentals

AQST Q4 2025 Earnings

Earnings Call

You can ask Aime

AQST

AQST fundamentals

AQST Q4 2025 Earnings

Earnings Call

AQST Earnings Call Summary for Q4/20258:00 AM on Mar 5, 2026

AQST Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

AQST Earnings Call Summary for Q2/20258:00 AM on Aug 12, 2025

AQST Earnings Call Summary for Q1/20258:00 AM on May 13, 2025

AQST Earnings Call Summary for Q4/20248:00 AM on Mar 6, 2025

You can ask Aime